Praxis Precision Medicines Inc (PRAX)

$345.30 -7.18 (-2.04%)
Market Cap 9.84B
Revenue (ttm) 0.00
Net Income (ttm) -303.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 382,900
Avg Vol 387,144
Day's Range N/A - N/A
Shares Out 27.92M
Stochastic %K 27%
Beta 2.76
Analysts Strong Sell
Price Target $636.84

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molec...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 300 8460
Address:
99 High Street, 30th Floor, Boston, United States
Trainguy1
Trainguy1 Sep. 7 at 4:00 PM
$PRAX After late-stage clinical failures cleared out Ulixacaltamide’s closest oral pipeline rivals: Jazz Pharmaceuticals’ Suvecaltamide and Sage Therapeutics’ SAGE-324, Ulixacaltamide’s current market competition consists of lower efficacy generic drugs, neurostimulation devices, and early-stage pipeline assets.
1 · Reply
Trainguy1
Trainguy1 Sep. 7 at 3:12 PM
$PRAX In the USA, 1 to 2 million out of the 7 to 10 million people who experience essential tremor use the beta blocker Propranolol. Praxis’s upcoming calcium channel inhibitor drug, Ulixacaltamide, if approved (PDUFA date Jan29, 2027) can be used on a stand-alone basis or as a combo drug with Propranolol to treat essential tremor. When used as a combo therapy, patients achieved a mean change of -1.07 on the modified Activities of Daily Living (mADL11) scale at week 8, compared to -0.61 for patients on propranolol and a placebo. At week 8, 48% of combo therapy patients achieved a clinically meaningful improvement, versus 25% of patients taking propranolol with a placebo. Propranolol is effective in 50% to 60% of patients who try it. About 10% to 15% of people who initially respond well to Propranolol will develop a drug tolerance after a year or more of use, requiring a prescription change.
0 · Reply
R84877P
R84877P Sep. 1 at 9:10 PM
$PRAX Ready for $400 already....
0 · Reply
Trainguy1
Trainguy1 Sep. 1 at 3:49 PM
$PRAX Praxis’s Relutrigine (PRAX-562) is an oral small molecule drug intended to treat developmental epileptic encephalopathies (DEEs) caused by SCN2A & SCN8A gene mutations. Relutrigine inhibits persistent sodium current channels. An NDA for the drug is currently being evaluated by the FDA, and is expected to be approved on or near Dec 27, 2026. Relutrigine’s principal competitor is Neurocrine (drug NBI-355), developed by Xenon Pharma. NBI-355 is currently undergoing a ph1b clinical trial. Data from the trial should be presented around the end of 2026.
0 · Reply
Brianum2011
Brianum2011 Aug. 31 at 8:02 PM
$SNDK $MU $SKHY $SLS $PRAX
0 · Reply
FactsPlease99
FactsPlease99 Aug. 31 at 12:36 PM
$XENE $BHVN $PRAX its gonna be battle with a crowded market with XENE, Biohaven, SK, and also Longboard! Doctors will be so bombarded and overwhelmed on Focal seizure treatments...basicaly all good seizure outcomes... Xenon and bio haven no titration is a big advantage and seizure freedom LT seems good for both. Xenon the soonest approval...Oh now let's throw in Praxis for some more fun!! dammmmm thats a lot of choices. 5 new drugs for Focal....
0 · Reply
topstockalerts
topstockalerts Aug. 31 at 12:13 PM
Pre Market Top Gainers PT2 $NCRA $LGPS $COOT $WBUY $PRAX
0 · Reply
gerryh57
gerryh57 Aug. 28 at 6:10 PM
$PRAX kind of love this, while I am upside down today, I can easily see this being my best investment of the year. Perspective total market volume 140,000 shares both buyers and sellers so 70,000 shares may have made me quite a bit….. took a bit to type that you know essential tremors and all
1 · Reply
R84877P
R84877P Aug. 28 at 4:28 PM
$PRAX This is a STEAL! buying discount
0 · Reply
glaucio
glaucio Aug. 28 at 4:07 PM
$PRAX we are safe , as as it keeps floating above $300
0 · Reply
Latest News on PRAX
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 3, 2026, 4:01 PM EDT - 6 days ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision price target raised to $575 from $470 at Goldman Sachs

2026-08-21T10:25:28.000Z - 20 days ago

Praxis Precision price target raised to $575 from $470 at Goldman Sachs

Praxis Precision price target raised to $945 from $765 at Raymond James

2026-08-17T13:20:18.000Z - 23 days ago

Praxis Precision price target raised to $945 from $765 at Raymond James

Praxis Precision price target raised to $462 from $449 at RBC Capital

2026-08-07T12:39:15.000Z - 4 weeks ago

Praxis Precision price target raised to $462 from $449 at RBC Capital

Praxis Precision price target raised to $514 from $400 at Baird

2026-08-07T12:01:15.000Z - 4 weeks ago

Praxis Precision price target raised to $514 from $400 at Baird

Praxis Precision price target raised to $362 from $323 at Wells Fargo

2026-08-07T11:00:47.000Z - 4 weeks ago

Praxis Precision price target raised to $362 from $323 at Wells Fargo

Praxis Precision Medicines Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 4 weeks ago

Praxis Precision Medicines Earnings Call Transcript: Q2 2026

Praxis Precision Medicines Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 4 weeks ago

Praxis Precision Medicines Earnings release: Q2 2026

Praxis Precision Medicines Quarterly report: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 4 weeks ago

Praxis Precision Medicines Quarterly report: Q2 2026

Praxis Precision Medicines Slides: Corporate presentation

Aug 6, 2026, 8:30 AM EDT - 4 weeks ago

Praxis Precision Medicines Slides: Corporate presentation

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Jul 30, 2026, 4:01 PM EDT - 5 weeks ago

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Praxis Precision initiated with a Buy at Goldman Sachs

2026-07-13T09:25:04.000Z - 1 month ago

Praxis Precision initiated with a Buy at Goldman Sachs

Praxis Precision, Remagine Labs announce research collaboration and license pact

2026-07-07T12:10:42.000Z - 2 months ago

Praxis Precision, Remagine Labs announce research collaboration and license pact

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Jul 7, 2026, 8:00 AM EDT - 2 months ago

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Jun 29, 2026, 4:30 PM EDT - 2 months ago

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision price target raised to $575 from $510 at Needham

2026-06-29T12:10:54.000Z - 2 months ago

Praxis Precision price target raised to $575 from $510 at Needham

Praxis Precision granted breakthrough therapy designation for elsunersen

2026-06-22T12:19:56.000Z - 2 months ago

Praxis Precision granted breakthrough therapy designation for elsunersen

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

Praxis Precision initiated with an Outperform at RBC Capital

2026-06-17T20:37:28.000Z - 2 months ago

Praxis Precision initiated with an Outperform at RBC Capital

Praxis Precision Medicines Transcript: AGM 2026

Jun 10, 2026, 9:00 AM EDT - 3 months ago

Praxis Precision Medicines Transcript: AGM 2026

Praxis Precision Medicines Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 3 months ago

Praxis Precision Medicines Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

Jun 4, 2026, 4:01 PM EDT - 3 months ago

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

Praxis Precision falls -15.4%

2026-06-02T16:19:35.000Z - 3 months ago

Praxis Precision falls -15.4%

Praxis Precision price target lowered to $616 from $715 at Truist

2026-06-02T13:37:44.000Z - 3 months ago

Praxis Precision price target lowered to $616 from $715 at Truist

Praxis Precision price target lowered to $650 from $750 at Oppenheimer

2026-06-02T12:23:18.000Z - 3 months ago

Praxis Precision price target lowered to $650 from $750 at Oppenheimer

Praxis Precision price target lowered to $162 from $166 at Wedbush

2026-06-02T12:07:49.000Z - 3 months ago

Praxis Precision price target lowered to $162 from $166 at Wedbush

Praxis Precision price target lowered to $810 from $843 at BTIG

2026-06-02T11:42:18.000Z - 3 months ago

Praxis Precision price target lowered to $810 from $843 at BTIG

Praxis Precision price target lowered to $400 from $433 at Baird

2026-06-02T11:24:46.000Z - 3 months ago

Praxis Precision price target lowered to $400 from $433 at Baird

Praxis Precision price target lowered to $1,201 from $1,245 at H.C. Wainwright

2026-06-02T10:27:13.000Z - 3 months ago

Praxis Precision price target lowered to $1,201 from $1,245 at H.C. Wainwright

Praxis Precision price target lowered to $374 from $420 at Deutsche Bank

2026-06-02T08:30:10.000Z - 3 months ago

Praxis Precision price target lowered to $374 from $420 at Deutsche Bank

Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study

Jun 1, 2026, 6:11 PM EDT - 3 months ago

Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study

Praxis Precision Medicines Provides Vormatrigine Program Update

Jun 1, 2026, 4:15 PM EDT - 3 months ago

Praxis Precision Medicines Provides Vormatrigine Program Update

Praxis Precision Medicines Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:20 PM EDT - 4 months ago

Praxis Precision Medicines Transcript: Bank of America Global Healthcare Conference 2026

Praxis Precision Medicines Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Praxis Precision Medicines Earnings Call Transcript: Q1 2026

Praxis Precision Medicines Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Praxis Precision Medicines Earnings release: Q1 2026

Praxis Precision Medicines Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Praxis Precision Medicines Quarterly report: Q1 2026

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 8:00 AM EDT - 4 months ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Praxis Precision Medicines Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 4 months ago

Praxis Precision Medicines Slides: Corporate presentation

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

May 4, 2026, 4:01 PM EDT - 4 months ago

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

Praxis Precision Medicines Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Praxis Precision Medicines Proxy statement: Proxy filing

Praxis Precision Medicines Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Praxis Precision Medicines Proxy statement: Proxy filing

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Apr 14, 2026, 7:30 AM EDT - 4 months ago

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

Mar 30, 2026, 4:01 PM EDT - 5 months ago

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

Praxis Precision Medicines Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:50 AM EST - 6 months ago

Praxis Precision Medicines Transcript: TD Cowen 46th Annual Health Care Conference

Praxis Precision Medicines Earnings Call Transcript: Q4 2025

Feb 19, 2026, 8:00 AM EST - 6 months ago

Praxis Precision Medicines Earnings Call Transcript: Q4 2025

Praxis Precision Medicines Earnings release: Q4 2025

Feb 19, 2026, 8:00 AM EST - 6 months ago

Praxis Precision Medicines Earnings release: Q4 2025

Praxis Precision Medicines Annual report: Q4 2025

Feb 19, 2026, 8:00 AM EST - 6 months ago

Praxis Precision Medicines Annual report: Q4 2025

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 19, 2026, 7:30 AM EST - 6 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Praxis Precision Medicines Slides: Corporate presentation

Feb 19, 2026, 7:00 AM EST - 6 months ago

Praxis Precision Medicines Slides: Corporate presentation

Praxis Precision Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 1:00 PM EST - 7 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

Feb 9, 2026, 4:01 PM EST - 7 months ago

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

Feb 2, 2026, 9:57 AM EST - 7 months ago

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 7 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Praxis Precision Medicines Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 8 months ago

Praxis Precision Medicines Slides: Corporate presentation

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

Jan 8, 2026, 4:45 PM EST - 8 months ago

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Jan 6, 2026, 11:15 PM EST - 8 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Jan 6, 2026, 4:03 PM EST - 8 months ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Dec 29, 2025, 8:00 AM EST - 8 months ago

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Dec 11, 2025, 8:00 AM EST - 9 months ago

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Dec 9, 2025, 4:01 PM EST - 9 months ago

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Dec 4, 2025, 4:10 PM EST - 9 months ago

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Dec 4, 2025, 4:01 PM EST - 9 months ago

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Praxis Precision Medicines Transcript: Fireside Chat

Nov 24, 2025, 1:00 PM EST - 9 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Nov 20, 2025, 4:01 PM EST - 9 months ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Praxis Precision Medicines Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 8:30 AM EST - 9 months ago

Praxis Precision Medicines Transcript: Jefferies London Healthcare Conference 2025

Praxis Precision Medicines Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 9:30 AM EST - 10 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Praxis Precision Medicines Slides: Corporate Presentation

Nov 10, 2025, 7:00 AM EST - 10 months ago

Praxis Precision Medicines Slides: Corporate Presentation

Praxis Precision Medicines Transcript: Fireside Chat

Nov 7, 2025, 12:30 PM EST - 10 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Praxis Precision Medicines Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Praxis Precision Medicines Earnings release: Q3 2025

Praxis Precision Medicines Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Praxis Precision Medicines Quarterly report: Q3 2025

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 10 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Oct 16, 2025, 11:45 PM EDT - 10 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Oct 16, 2025, 2:14 PM EDT - 10 months ago

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Oct 16, 2025, 12:02 PM EDT - 10 months ago

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Praxis Precision Medicines Transcript: Study Result

Oct 16, 2025, 8:00 AM EDT - 10 months ago

Praxis Precision Medicines Transcript: Study Result

Praxis Precision Medicines Press release: Study Result

Oct 16, 2025, 8:00 AM EDT - 10 months ago

Praxis Precision Medicines Press release: Study Result

Praxis Precision Medicines Slides: Study Result

Oct 16, 2025, 8:00 AM EDT - 10 months ago

Praxis Precision Medicines Slides: Study Result

Praxis Precision Medicines' movement disorder drug shows promise in trials

Oct 16, 2025, 7:09 AM EDT - 10 months ago

Praxis Precision Medicines' movement disorder drug shows promise in trials

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

Sep 29, 2025, 7:00 AM EDT - 11 months ago

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

Praxis Precision Medicines Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 8:30 AM EDT - 12 months ago

Praxis Precision Medicines Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Praxis Precision Medicines to Participate in September Investor Conferences

Sep 4, 2025, 4:01 PM EDT - 1 year ago

Praxis Precision Medicines to Participate in September Investor Conferences

Praxis Precision Medicines Transcript: Post-IEC Discussion with Praxis Precision Medicines (PRAX) Webinar

Sep 2, 2025, 10:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Post-IEC Discussion with Praxis Precision Medicines (PRAX) Webinar

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

Aug 25, 2025, 4:01 PM EDT - 1 year ago

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

Praxis Precision Medicines Transcript: Fireside Chat

Aug 7, 2025, 11:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Fireside Chat

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 5, 2025, 5:50 PM EDT - 1 year ago

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Praxis Precision Medicines Transcript: Fireside Chat

Aug 5, 2025, 10:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Fireside Chat

Praxis Precision Medicines Slides: Fireside Chat

Aug 5, 2025, 10:00 AM EDT - 1 year ago

Praxis Precision Medicines Slides: Fireside Chat

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 8:30 AM EDT - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Praxis Precision Medicines Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

Praxis Precision Medicines Earnings Call Transcript: Q2 2025

Praxis Precision Medicines Quarterly report: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

Praxis Precision Medicines Quarterly report: Q2 2025

Praxis Precision Medicines Earnings release: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

Praxis Precision Medicines Earnings release: Q2 2025

Praxis Precision Medicines Slides: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

Praxis Precision Medicines Slides: Q2 2025

Praxis Precision Medicines Slides: Corporate Presentation

Aug 3, 2025, 5:00 PM EDT - 1 year ago

Praxis Precision Medicines Slides: Corporate Presentation

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Jul 17, 2025, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision Medicines Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 8:10 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Jefferies Global Healthcare Conference 2025

Praxis Precision Medicines Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 9:30 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Praxis Precision Medicines Transcript: Status Update

May 2, 2025, 10:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Status Update

Praxis Precision Medicines Press release: Status Update

May 2, 2025, 10:00 AM EDT - 1 year ago

Praxis Precision Medicines Press release: Status Update

Praxis Precision Medicines Slides: Status Update

May 2, 2025, 10:00 AM EDT - 1 year ago

Praxis Precision Medicines Slides: Status Update

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 2, 2025, 8:30 AM EDT - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Praxis Precision Medicines Quarterly report: Q1 2025

May 2, 2025, 8:30 AM EDT - 1 year ago

Praxis Precision Medicines Quarterly report: Q1 2025

Praxis Precision Medicines Earnings release: Q1 2025

May 2, 2025, 8:30 AM EDT - 1 year ago

Praxis Precision Medicines Earnings release: Q1 2025

Praxis Precision Medicines Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines Proxy statement: Proxy Filing

Praxis Precision Medicines Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines Proxy statement: Proxy Filing

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Praxis Precision Medicines Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 11:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: 24th Annual Needham Virtual Healthcare Conference

Praxis Precision Medicines to Participate in Upcoming April Conferences

Apr 3, 2025, 5:00 PM EDT - 1 year ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines Transcript: UBS Virtual CNS Day 2025

Mar 17, 2025, 9:30 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: UBS Virtual CNS Day 2025

Praxis Precision Medicines Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 12, 2025, 2:30 PM EDT - 1 year ago

Praxis Precision Medicines Transcript: Barclays 27th Annual Global Healthcare Conference

Praxis Precision Medicines Transcript: Leerink’s Global Healthcare Conference 2025

Mar 10, 2025, 3:40 PM EDT - 1 year ago

Praxis Precision Medicines Transcript: Leerink’s Global Healthcare Conference 2025

Praxis Precision Medicines Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 9:10 AM EST - 1 year ago

Praxis Precision Medicines Transcript: TD Cowen 45th Annual Healthcare Conference

Praxis Precision Medicines Earnings release: Q4 2024

Feb 28, 2025, 9:30 AM EST - 1 year ago

Praxis Precision Medicines Earnings release: Q4 2024

Praxis Precision Medicines Annual report: Q4 2024

Feb 28, 2025, 9:30 AM EST - 1 year ago

Praxis Precision Medicines Annual report: Q4 2024

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Feb 28, 2025, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Praxis Precision Medicines Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 11, 2025, 11:20 AM EST - 1 year ago

Praxis Precision Medicines Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Praxis Precision Medicines Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 2:30 PM EST - 1 year ago

Praxis Precision Medicines Transcript: Guggenheim SMID Cap Biotech Conference

Praxis Precision Medicines to Present at Two February Investor Conferences

Feb 3, 2025, 5:00 PM EST - 1 year ago

Praxis Precision Medicines to Present at Two February Investor Conferences

Praxis Precision Medicines Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

Praxis Precision Medicines Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Jan 12, 2025, 9:00 PM EST - 1 year ago

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dec 18, 2024, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

Dec 5, 2024, 8:30 AM EST - 1 year ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB STOK WGS

Trainguy1
Trainguy1 Sep. 7 at 4:00 PM
$PRAX After late-stage clinical failures cleared out Ulixacaltamide’s closest oral pipeline rivals: Jazz Pharmaceuticals’ Suvecaltamide and Sage Therapeutics’ SAGE-324, Ulixacaltamide’s current market competition consists of lower efficacy generic drugs, neurostimulation devices, and early-stage pipeline assets.
1 · Reply
Trainguy1
Trainguy1 Sep. 7 at 3:12 PM
$PRAX In the USA, 1 to 2 million out of the 7 to 10 million people who experience essential tremor use the beta blocker Propranolol. Praxis’s upcoming calcium channel inhibitor drug, Ulixacaltamide, if approved (PDUFA date Jan29, 2027) can be used on a stand-alone basis or as a combo drug with Propranolol to treat essential tremor. When used as a combo therapy, patients achieved a mean change of -1.07 on the modified Activities of Daily Living (mADL11) scale at week 8, compared to -0.61 for patients on propranolol and a placebo. At week 8, 48% of combo therapy patients achieved a clinically meaningful improvement, versus 25% of patients taking propranolol with a placebo. Propranolol is effective in 50% to 60% of patients who try it. About 10% to 15% of people who initially respond well to Propranolol will develop a drug tolerance after a year or more of use, requiring a prescription change.
0 · Reply
R84877P
R84877P Sep. 1 at 9:10 PM
$PRAX Ready for $400 already....
0 · Reply
Trainguy1
Trainguy1 Sep. 1 at 3:49 PM
$PRAX Praxis’s Relutrigine (PRAX-562) is an oral small molecule drug intended to treat developmental epileptic encephalopathies (DEEs) caused by SCN2A & SCN8A gene mutations. Relutrigine inhibits persistent sodium current channels. An NDA for the drug is currently being evaluated by the FDA, and is expected to be approved on or near Dec 27, 2026. Relutrigine’s principal competitor is Neurocrine (drug NBI-355), developed by Xenon Pharma. NBI-355 is currently undergoing a ph1b clinical trial. Data from the trial should be presented around the end of 2026.
0 · Reply
Brianum2011
Brianum2011 Aug. 31 at 8:02 PM
$SNDK $MU $SKHY $SLS $PRAX
0 · Reply
FactsPlease99
FactsPlease99 Aug. 31 at 12:36 PM
$XENE $BHVN $PRAX its gonna be battle with a crowded market with XENE, Biohaven, SK, and also Longboard! Doctors will be so bombarded and overwhelmed on Focal seizure treatments...basicaly all good seizure outcomes... Xenon and bio haven no titration is a big advantage and seizure freedom LT seems good for both. Xenon the soonest approval...Oh now let's throw in Praxis for some more fun!! dammmmm thats a lot of choices. 5 new drugs for Focal....
0 · Reply
topstockalerts
topstockalerts Aug. 31 at 12:13 PM
Pre Market Top Gainers PT2 $NCRA $LGPS $COOT $WBUY $PRAX
0 · Reply
gerryh57
gerryh57 Aug. 28 at 6:10 PM
$PRAX kind of love this, while I am upside down today, I can easily see this being my best investment of the year. Perspective total market volume 140,000 shares both buyers and sellers so 70,000 shares may have made me quite a bit….. took a bit to type that you know essential tremors and all
1 · Reply
R84877P
R84877P Aug. 28 at 4:28 PM
$PRAX This is a STEAL! buying discount
0 · Reply
glaucio
glaucio Aug. 28 at 4:07 PM
$PRAX we are safe , as as it keeps floating above $300
0 · Reply
Trainguy1
Trainguy1 Aug. 24 at 3:33 PM
$PRAX This graphic shows PRAX's forecasted peak sales projections for their products that have passed or are undergoing ph3 trials. You can see these add up to $20 billion/yr. If PRAX were to be acquired, Google AI says you can estimate the acquisition price as follows: To estimate a central nervous system (CNS) biotech company's acquisition price, multiply its projected peak sales by a valuation multiple of 3.5x to 5.5x for Phase 3 assets (or 2.0x to 3.5x if still in early Phase 3 with high regulatory risk), then adjust for net cash and probability of success. You do the math.
2 · Reply
JFDI
JFDI Aug. 21 at 2:30 PM
$PRAX thin 2 in
0 · Reply
Trainguy1
Trainguy1 Aug. 21 at 12:49 PM
$PRAX I appreciate the highly ranked women of Wall Street who analyze Praxis. Look at these analysts rankings and their 1-year share price forecasts. They tell us to anticipate share price growth of at least 40%. I trust that my investment in PRAX will grow to at least match the low-end forecast, and will very likely surpass it. * Ritu Baral, ranked #55 of 12,492. 1 yr PRAX share price forecast: $510/sh * Ami Fadia, ranked #78 of 12,492. 1 yr PRAX share price forecast: $582 * Yasmeen Rahimi, ranked #156 of 12,489. 1 yr PRAX share price forecast: $1200
0 · Reply
AngusMacbeth
AngusMacbeth Aug. 20 at 5:26 PM
$PRAX Adding a few today. When those FDA approvals come in folks will wish they bought here.
1 · Reply
Brianum2011
Brianum2011 Aug. 19 at 10:52 PM
$SLS $PRAX
0 · Reply
R84877P
R84877P Aug. 19 at 7:40 PM
$PRAX Flying high
0 · Reply
Quantumup
Quantumup Aug. 17 at 1:04 PM
Raymond James⬆️ $RAPP's PT to $75, reiterated Strong Buy and said -- We believe RAP-219's bipolar mania readout is one of the most asymmetric catalysts in SMID biotech. $XENE $PRAX OVID ESAIY BHVN Here's what Raymond James went on to say: https://x.com/Quantumup1/status/2089337204015276259?s=20
0 · Reply
Quantumup
Quantumup Aug. 17 at 10:35 AM
Raymond James⬆️ $PRAX's PT to $945, reiterated Strong Buy and said -- The next 6-12 months for Praxis represent one of the most compelling setups in SMID biotech. $JAZZ $UCBJY RAPP XENE ESAIY BHVN OVID Here's what else Raymond James had to say: https://x.com/Quantumup1/status/2089299818636054544?s=20
0 · Reply
JodieChristy
JodieChristy Aug. 7 at 9:46 PM
Biotech Valuation Overload? My Top 4 High-Conviction Value Picks To Outsmart The Market! $INSM is trading strong around $131.10 right now! $PTGX is trading strong around $146.00 right now! $BBIO is trading strong around $84.48 right now! $PRAX is trading strong around $360.76 right now! While the broader biotech sector looks insanely overvalued, I filter strictly for late-stage clinical or early commercial winners featuring elite management, massive broad pipelines, $10B+ peak sales potential, and prices at or below intrinsic value. My current high-conviction watchlist features exactly four names: $INSM,$PTGX, $BBIO, and$PRAX.[Live Trading Strategy]: Avoid chasing overpriced hype scale into key support levels methodically and let value do the heavy lifting!
3 · Reply
Trainguy1
Trainguy1 Aug. 7 at 5:15 PM
$PRAX Clinical & Pipeline Milestones — Q4 2026: Topline data expected from the EMERALD trial for relutrigine in broad DEEs. Late 2026 / 2027: Amended study designs and progress updates for the vormatrigine epilepsy program following initial trial re-evaluations. 2027: Expected topline results for the elsunersen EMBRAVE3 registrational trial in early-seizure-onset SCN2A DEE.
0 · Reply
Trainguy1
Trainguy1 Aug. 7 at 5:05 PM
$PRAX Upcoming PDUFA Dates - December 27, 2026: Relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). January 29, 2027: Ulixacaltamide for the treatment of essential tremor (ET) in adults.
0 · Reply
NoHandOutz
NoHandOutz Aug. 7 at 1:24 PM
$IOVA $SITM $PRAX ZENA drone manufacturer is getting a big squeeze this morning!!
1 · Reply